Corporate ActionOct 2, 2026, 04:52 PM
Sunshine Biopharma Files S-1 for Unit Offering Up to $7M
AI Summary
Sunshine Biopharma Inc. has filed an S-1 registration statement for an offering of up to 10,180,337 common units, each consisting of one share of common stock and two Series D Warrants. The company is also offering pre-funded units as an alternative for certain investors. The offering is being conducted on a best efforts basis with Aegis Capital Corp. acting as the exclusive placement agent. The company anticipates raising approximately $6.0 million in net proceeds, which will be used for general corporate purposes, including working capital. The common stock is listed on Nasdaq under the symbol SBFM.
Key Highlights
- Sunshine Biopharma Inc. is offering up to 10,180,337 common units, each with one share of common stock and two Series D Warrants.
- The offering also includes up to 10,180,337 pre-funded units, each with a pre-funded warrant and two Series D Warrants.
- The assumed public offering price is $0.6876 per common unit, based on the last reported sale price.
- The company expects to raise approximately $6.0 million in net proceeds for general corporate purposes.
- The Series D Warrants have an initial exercise price of $0.6876 and are exercisable for five years.
- Pre-funded warrants have a nominal exercise price of $0.00001 and no expiration date.
- The company's common stock is listed on The Nasdaq Capital Market under the symbol 'SBFM'.
Price Impact
More from SBFM